Van Maldergem Syndrome — Comprehensive Disease Characteristics Report

Disease: Van Maldergem Syndrome (VMS) Category: Mendelian (rare autosomal recessive multisystem congenital disorder) Suggested MONDO: MONDO:0018852 (Van Maldergem syndrome). Subtypes: VMLDS1 (MONDO:0010875-class, DCHS1), VMLDS2 (FAT4).

Evidence source note: VMS is an ultra-rare disorder. Essentially all knowledge is derived from individual patient case reports and small case series (aggregated disease-level resources such as OMIM/Orphanet compile these), supplemented by model-organism (mouse, zebrafish, Drosophila) and in vitro mechanistic studies. There are no EHR-scale cohorts, registries, clinical trials, GWAS, or population omics datasets for this disease. Frequencies below are therefore qualitative/small-denominator estimates, not population statistics.

1. Disease Information

Overview. Van Maldergem syndrome is a rare autosomal recessive multiple-congenital-anomaly/intellectual-disability syndrome first described by Van Maldergem and colleagues in 1992. Its cardinal features are a distinctive craniofacial (blepharo-naso-facial) gestalt, intellectual disability, auditory (external/middle ear) malformations with conductive hearing loss, hand/digit anomalies and skeletal abnormalities, and — characteristically — periventricular and subcortical neuronal heterotopia on brain imaging (P22473091 P27739185). It is caused by biallelic loss-of-function variants in one of two atypical cadherin genes, DCHS1 (type 1) or FAT4 (type 2), which act as a receptor–ligand pair in Fat–Dachsous planar cell polarity (PCP)/Hippo signaling (P24056717).

Key identifiers. - OMIM: #601390 — Van Maldergem syndrome 1 (VMLDS1; DCHS1); #615546 — Van Maldergem syndrome 2 (VMLDS2; FAT4). MIM#601390 explicitly cited in P25930014 and P40797481. - Orphanet: ORPHA:314679 (Van Maldergem syndrome). - ICD-10: Q87.8 (other specified congenital malformation syndromes, not elsewhere classified); ICD-11: LD2F.1Y / LD2F.0Y class (multiple developmental anomalies). No VMS-specific ICD code. - MeSH: No dedicated MeSH heading; indexed under "Abnormalities, Multiple" / "Intellectual Disability" and gene terms DCHS1, FAT4. - MONDO: MONDO:0018852 (parent), with type-1/type-2 children.

Synonyms / alternative names. Van Maldergem syndrome 1 and 2 (VMLDS1/VMLDS2); "blepharo-naso-facial malformation with intellectual disability" (descriptive); historically overlapping with, and now recognized as allelic to, Hennekam lymphangiectasia–lymphedema syndrome when caused by FAT4 (P24913602 P29681106).

2. Etiology

Primary cause — genetic. VMS is monogenic and recessive. It is caused by biallelic (homozygous or compound heterozygous) pathogenic variants in: - DCHS1 (Dachsous cadherin-related 1; HGNC:13681; NCBI Gene 8642; chromosome 11p15.4; OMIM 603057) → VMLDS1. - FAT4 (FAT atypical cadherin 4; HGNC:23109; NCBI Gene 79633; chromosome 4q28.1; OMIM 612411) → VMLDS2.

"Here we show that mutations in genes encoding the receptor-ligand cadherin pair DCHS1 and FAT4 lead to a recessive syndrome in humans that includes periventricular neuronal heterotopia." (P24056717)

Risk factors. - Genetic: The two causal genes are the only established risk determinants. Consanguinity is a major risk amplifier — parental consanguinity was present in 3/5 families in the defining cohort, and homozygous variants predominate in consanguineous pedigrees (P22473091). No susceptibility loci or GWAS signals exist (disease is monogenic). Potential modifier effects (e.g., FAT4 vs DCHS1 genotype, allelic CCBE1/ADAMTS3 interactions in the lymphatic-overlap phenotype) are hypothesized but unproven. - Environmental / lifestyle / infectious: None identified. VMS is fully genetically determined; no toxin, teratogen, dietary, occupational, or infectious contributor is known or expected. (Not applicable.)

Protective factors. None described. In principle, inheriting only one variant allele (heterozygous carrier) is "protective" in the Mendelian sense — carriers are unaffected — but no protective modifier alleles are known.

Gene–environment interactions. Not applicable/none reported; the phenotype is determined by biallelic genotype independent of environment.

3. Phenotypes

VMS is a congenital, multisystem, generally non-progressive disorder; most features are present at birth or emerge in infancy, with intellectual disability apparent in childhood. Severity is variable (mild-to-moderate ID is typical). Frequencies are qualitative given the tiny reported population (~dozens of patients worldwide).

Craniofacial (physical manifestations — near-universal / "typical facial gestalt"): - Blepharophimosis (HP:0000581); telecanthus (HP:0000506); maxillary/midface hypoplasia (HP:0000327/HP:0011800); microtia (HP:0008551); atresia of external auditory canal (HP:0000413); blepharo-naso-facial malformation. (P22473091 P27739185)

Auditory (clinical sign — near-universal): - Conductive hearing impairment (HP:0000405), bilateral, from microtia + aural atresia ± middle-ear/ossicular and tympanic-cavity malformations. "Almost all nine described patients have been shown to be affected by conductive hearing impairment attributed to microtia, and atresia of the outer ear canal." (P27739185)

Neurological / neurodevelopmental (near-universal): - Intellectual disability, mild-to-moderate (HP:0001249); neonatal hypotonia (HP:0001319); periventricular nodular heterotopia (HP:0032388) and subcortical/subependymal neuronal heterotopia (HP:0002518); altered functional cerebral asymmetry (P25930014); poor coordination/clumsiness (HP:0002317). (P22473091 P24056717)

Skeletal / limb (common): - Digital contractures/camptodactyly (HP:0100490/HP:0012385); brachydactyly / short 4th metacarpal (HP:0001156); scoliosis (HP:0002650); osteopenia (HP:0000938); general skeletal anomalies. (P22473091 P28878612 P40797481 P29681106)

Neonatal / feeding / respiratory (common): - Feeding difficulties (HP:0011968); respiratory problems and tracheal anomalies (HP:0002778); failure to thrive (HP:0001508). (P22473091 P29681106)

Endocrine (rare/variable): - Hypogonadotropic hypogonadism (HP:0000044); breast aplasia/hypoplasia/amazia with normal nipples (HP:0100783/HP:0003187) (P29046692); central precocious puberty (HP:0000826) (P40797481).

Genitourinary (rare/variable): - Unilateral renal agenesis (HP:0000122/HP:0000104); ureterovesical junction obstruction/urinary tract obstruction (HP:0000073); duplex/duplicated collecting system (HP:0000081). (P28878612 P30853441)

Gastrointestinal / lymphatic (rare): - Intestinal lymphangiectasia (HP:0002593) — reported in VMS and blurring the boundary with Hennekam syndrome (P31063239).

Quality-of-life impact. No formal EQ-5D/SF-36/PROMIS data exist. Inferred burden: lifelong intellectual disability and hearing loss impair communication, learning, and independence; feeding/respiratory issues and multiple surgeries burden infancy; craniofacial differences carry psychosocial impact. Hearing rehabilitation measurably improves social skills and language (P26491591).

4. Genetic / Molecular Information

Causal genes. | Gene | Locus | OMIM | Protein | Disease | |---|---|---|---|---| | DCHS1 (HGNC:13681, Gene 8642) | 11p15.4 | 603057 | Dachsous 1 (protocadherin, PCP ligand) | VMLDS1 (#601390) | | FAT4 (HGNC:23109, Gene 79633) | 4q28.1 | 612411 | FAT4 (protocadherin, PCP receptor) | VMLDS2 (#615546) |

DCHS1 and FAT4 form a receptor–ligand pair; FAT4 is a very large single-pass transmembrane protein with 34 extracellular cadherin repeats, EGF-like domains, and laminin-G–like domains; DCHS1 is its Dachsous-family cadherin ligand (P28488382).

Pathogenic variants. - Type/class: predominantly loss-of-function — nonsense, frameshift, and canonical splice-site variants (e.g., FAT4 NM_024582.6:c.7018+1G>A, loss of the intron-6 donor site, ACMG pathogenic; P37551355), as well as missense variants. Compound heterozygous and homozygous configurations both occur (P29046692 P28878612). - Classification: Reported variants are curated as pathogenic / likely pathogenic by ACMG/AMP criteria; novel variants continue to be reported, some initially VUS pending segregation/functional data (P31384091 P40797481). - Allele frequency: Individually rare/private; consistent with a recessive ultra-rare disease, biallelic pathogenic genotypes are essentially absent from gnomAD, though single heterozygous LoF alleles exist at very low frequency. - Origin: Germline, biallelic. (Somatically, FAT4 is a tumor-suppressor mutated in cancers, but that is unrelated to the germline VMS phenotype; P28488382 notes FAT4's tumor-suppressor role.) - Functional consequence: Loss of function of the Dchs1–Fat4 PCP/Hippo module. A 2026 study shows the DCHS1 intracellular domain is functionally critical — its loss expands neurogenic proliferation and generates VMS-like defects (P41972678).

Modifier genes. None validated. Phenotype-modifying candidates include the specific gene affected (FAT4 vs DCHS1) and, for the lymphatic-overlap phenotype, the allelic lymphangiogenesis genes CCBE1 and ADAMTS3 (which also cause Hennekam syndrome) (P29681106).

Epigenetics. No DNA-methylation, histone-modification, or episignature data specific to VMS are available (not applicable at present).

Chromosomal abnormalities. VMS is a single-gene disorder; no recurrent aneuploidy, translocation, or copy-number syndrome. Chromosomal microarray is typically normal (useful mainly to exclude CNV mimics).

5. Environmental Information

(All "Not applicable" — VMS is entirely genetically determined.)

6. Mechanism / Pathophysiology

Core molecular pathway — Fat–Dachsous PCP and Hippo/YAP signaling. DCHS1 (Dachsous) and FAT4 are the vertebrate orthologs of the Drosophila Dachsous–Fat PCP system. They bind heterophilically across cell membranes and are expressed in complementary gradients that provide directional (planar polarity) information to tissues, feeding into the Hippo kinase cascade to restrain the transcriptional co-activator YAP (P24056717 P24998526). GO/pathway terms: planar cell polarity pathway (GO:0090175), Hippo signaling (GO:0035329), homophilic cell–cell adhesion via plasma-membrane adhesion molecules (GO:0007156), Reactome "Signaling by Hippo."

Causal chain (neurodevelopment — best-characterized): 1. Trigger (upstream): Biallelic LoF of DCHS1 or FAT4 → loss of Fat–Dachsous PCP signaling in the embryonic neuroepithelium. 2. De-repression of YAP: Hippo signaling is disrupted → YAP (Hippo effector) is inappropriately active.

"These effects were countered by concurrent knockdown of Yap, a transcriptional effector of the Hippo signaling pathway. These findings implicate Dchs1 and Fat4 upstream of Yap as key regulators of mammalian neurogenesis." (P24056717) 3. Cellular consequence: Expanded neural progenitor proliferation with reduced neuronal differentiation → excess progenitors. Confirmed by DCHS1-intracellular-domain loss expanding neurogenic proliferation (P41972678). 4. Migration failure: Loss of Dchs1/Fat4 expression gradients disrupts collective tangential neuronal migration and planar polarity (P24998526). 5. Clinical manifestation (downstream): Neurons fail to reach the cortical plate → periventricular/subcortical neuronal heterotopia, intellectual disability, and altered functional cerebral asymmetry (P24056717 P25930014).

Parallel causal chains in other organs (same module, tissue-specific outputs): - Bone/craniofacial: Dchs1–Fat4 regulates osteoblast differentiation; its disruption produces the craniofacial abnormalities of VMS (P31358536). → maxillary hypoplasia, skeletal anomalies, osteopenia. - Kidney: FAT4 fine-tunes kidney development by regulating RET receptor-tyrosine-kinase signaling; Fat4 deletion causes duplex-kidney phenotypes (P30853441). → renal agenesis/duplex kidney/urinary obstruction. - Cytoskeleton (early embryo): Dchs1 influences actin and microtubule organization, partly independent of Fat, via its intracellular domain (zebrafish; P26160902). - Neuronal maintenance: Drosophila fat loss in neurons impairs neuromuscular-junction structure and axonal targeting (P28488382).

Cellular processes: cell proliferation/cell-cycle control (GO:0008283), neuron differentiation (GO:0030182), neuron migration (GO:0001764), osteoblast differentiation (GO:0001649), establishment of planar polarity (GO:0001736). Cell types (CL): radial glial/neural progenitor cells (CL:0000047 / CL:0000031), migrating neurons (CL:0000540), osteoblasts (CL:0000062), ureteric-bud/renal epithelial cells (CL:1000454). Subcellular (GO CC): plasma membrane (GO:0005886), cell–cell junction (GO:0005911), actin cytoskeleton (GO:0015629), microtubule (GO:0005874); YAP acts in the nucleus (GO:0005634).

Protein dysfunction: loss of function of large transmembrane protocadherins (adhesion/signaling), not misfolding/aggregation. Metabolic changes: none characteristic. Immune involvement: none (not an immune disease). Tissue-damage mechanism: developmental malformation/dysplasia (failed morphogenesis) rather than degeneration, ischemia, or fibrosis. Molecular profiling (transcriptomics/proteomics/metabolomics/lipidomics): no patient-derived omics datasets available. Functional genomics: mechanistic knockdown/knockout screens in mouse/zebrafish/fly and YAP-epistasis (above) constitute the functional evidence.

7. Anatomical Structures Affected

Organ / system level (primary): - Nervous system (UBERON:0001016): cerebral cortex (UBERON:0000956), periventricular white matter/lateral ventricle margins (UBERON:0002289) — heterotopia; brainstem branchiomotor nuclei (migration). Body system: nervous. - Ear (UBERON:0001690): external ear/auricle (UBERON:0001757) — microtia; external auditory canal (UBERON:0001352) — atresia; middle ear / ossicles / tympanic cavity (UBERON:0001756) — malformation (P27739185). Body system: special sensory/auditory. - Craniofacial skeleton & face (UBERON:0001456 face; UBERON:0001684 mandible/maxilla UBERON:0002397): midface/maxillary hypoplasia. - Skeleton / limbs (UBERON:0002091): hands/digits (UBERON:0002389), vertebral column (UBERON:0002415) — contractures, brachydactyly, scoliosis, osteopenia.

Secondary / variable organ involvement: - Kidney/urinary tract (UBERON:0002113 kidney; UBERON:0000056 ureter): agenesis, duplex kidney, ureterovesical obstruction (P28878612 P30853441). - Endocrine/reproductive (UBERON:0000990 reproductive system; hypothalamic–pituitary–gonadal axis): hypogonadotropic hypogonadism, precocious puberty; breast (UBERON:0000310) aplasia (P29046692 P40797481). - Respiratory tract / trachea (UBERON:0003126): tracheal anomalies, respiratory problems (P29681106). - Gastrointestinal/lymphatic (UBERON:0002108 small intestine; lymphatic vessels UBERON:0001473): intestinal lymphangiectasia (P31063239).

Tissue level: neuroepithelium/neural tissue, connective/skeletal tissue (bone), epithelial tissues (renal, otic). Cell level (CL): neural progenitors/radial glia, migrating neurons, osteoblasts, renal epithelial cells (see §6). Subcellular (GO CC): plasma membrane, cell–cell junctions, cytoskeleton; nuclear YAP.

Localization / lateralization: brain heterotopia typically bilateral; ear/hearing involvement bilateral; renal malformations may be unilateral (e.g., unilateral renal agenesis, P28878612). Notably, functional cerebral asymmetry is increased (P25930014).

8. Temporal Development

9. Inheritance and Population

Epidemiology. Ultra-rare. Orphanet prevalence class <1/1,000,000; fewer than ~50 patients reported worldwide since 1992 (only ~9 described by 2016–2017; P27739185). Incidence not quantifiable. No registry/GBD data.

Inheritance & genetics. - Pattern: Autosomal recessive for both DCHS1 and FAT4 forms (P22473091 P24056717). - Penetrance: Essentially complete in biallelic individuals (all reported biallelic patients are affected), though expressivity is variable (organ involvement and severity differ between patients, even within the same gene). - Anticipation: None (not a repeat-expansion disorder). - Germline mosaicism: Not specifically reported. - Consanguinity: Important risk factor — parental consanguinity in 3/5 defining families; homozygous variants common in consanguineous unions (P22473091). - Founder effects: None established; variants are largely private. - Carrier frequency: Not formally estimated; expected very low. Heterozygous carriers are asymptomatic.

Population demographics. - Affected populations: Reported across diverse ancestries (European, Middle Eastern, Chinese, Macedonian, etc.; PMIDs 22473091, 40797481, 28878612) — no ethnic predilection beyond enrichment where consanguinity is common. - Geographic distribution: Worldwide, non-endemic. - Sex ratio: No clear sex bias; both sexes affected (autosomal). Some sex-specific manifestations reported (breast aplasia/hypogonadism in a female, P29046692). - Age distribution: Diagnosed from newborn period (P29505454) through adulthood (retrospective WES at age 37, P29046692).

10. Diagnostics

Genetic testing (definitive). - Approach: Molecular confirmation of biallelic pathogenic variants in DCHS1 or FAT4. Whole-exome sequencing (WES) is the principal diagnostic modality and has repeatedly established the diagnosis, including via reverse phenotyping and expanded carrier screening of parents (P37551355 P29046692 P28878612 P31384091). WGS is an alternative that also detects deep-intronic/structural variants. Multigene panels for intellectual disability / periventricular heterotopia / malformation syndromes should include DCHS1, FAT4, and — given phenotypic overlap — CCBE1 and ADAMTS3 (Hennekam). Single-gene testing is reasonable when the gestalt is classic. Chromosomal microarray/karyotype/FISH are typically normal and serve to exclude CNV/aneuploidy mimics. Mitochondrial and repeat-expansion testing are not indicated.

Imaging & clinical tests. - Brain MRI: periventricular nodular and subcortical heterotopia — a recognizable pattern that, in the right clinical context, should prompt targeted testing (P39462795 P24056717). - Temporal-bone high-resolution CT: external/middle-ear and tympanic-cavity malformations (P27739185). - Audiology: confirms conductive hearing loss; EEG documented altered functional cerebral asymmetry in a research setting (P25930014). - Renal ultrasound/urography: for renal agenesis/duplex kidney/obstruction (P28878612). - Endocrine labs: gonadotropins/sex steroids for hypogonadotropic hypogonadism or precocious puberty (P29046692 P40797481).

Biomarkers / omics diagnostics: No specific biochemical biomarker; DNA sequence variants are the diagnostic marker. No validated RNA/proteomic/metabolomic/epigenomic test; no liquid biopsy role.

Clinical criteria & differential diagnosis. No formal consensus criteria; diagnosis rests on the characteristic facial gestalt + hearing loss + intellectual disability + neuronal heterotopia, confirmed genetically. Differential diagnoses: Hennekam syndrome (allelic FAT4; distinguished classically by lymphedema — though intestinal lymphangiectasia can overlap; P31063239 P29681106); other periventricular-heterotopia disorders (FLNA-related; ARFGEF2-related; EML1-associated) (P39462795); blepharophimosis-ptosis-epicanthus-inversus syndrome (BPES, FOXL2); other multiple-congenital-anomaly/ID syndromes.

Screening. Not part of newborn screening. Cascade/carrier screening of relatives once the familial variants are known; expanded carrier screening can identify at-risk couples (P37551355). Prenatal/preimplantation testing feasible for known familial variants.

11. Outcome / Prognosis

12. Treatment

No disease-modifying or curative therapy exists. Management is multidisciplinary, supportive, and symptom-directed (NCIT: Supportive Care, C15277).

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

VMS mechanism has been dissected chiefly in animal models (mammalian and invertebrate); no established patient-derived organoid/iPSC model is prominent in the literature to date.

Applications: these models establish the Dchs1–Fat4 → Hippo/YAP axis in neurogenesis, PCP-driven neuronal migration, osteogenesis, and nephrogenesis, and provide platforms for testing pathway-directed interventions (e.g., YAP modulation). Limitations: partial phenotype coverage per model; species differences in ear/craniofacial anatomy; absence of a comprehensive humanized model.

Summary of Supported vs. Refuted Hypotheses

Supported (evidence-based): - VMS is autosomal recessive, caused by biallelic DCHS1 (VMLDS1) or FAT4 (VMLDS2) LoF variants (P24056717 P22473091). - Periventricular heterotopia arises from loss of Dchs1/Fat4 → YAP de-repression → excess progenitor proliferation/failed differentiation and migration (P24056717 P24998526 P41972678). - The same module drives craniofacial/skeletal (osteoblast) and renal (FAT4–RET) phenotypes (P31358536 P30853441). - VMS and Hennekam syndrome are allelic FAT4 disorders on a phenotypic spectrum (P24913602 P29681106 P31063239). - Conductive hearing loss from ear malformation is near-constant and implant-treatable (P27739185 P26491591).

Refuted / not supported: No environmental, infectious, or lifestyle etiology; no anticipation; no evidence for a progressive/degenerative course (features are static, P40797481).

Limitations & Future Directions

Key References (PMID)

41972678, 40797481, 39462795, 37551355, 31384091, 31358536, 31063239, 30853441, 29681106, 29505454, 29046692, 28878612, 28488382, 27739185, 26491591, 26160902, 25930014, 24998526, 24913602, 24056717, 22473091.